northalrugosidine

antileishmanial bisbenzyltetrahydroisoquinoline alkaloid from Thalictrum alpinum; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Visceral Leishmaniasis (Kala Azar) 03/27/2015 - "Northalrugosidine was tested in vivo using a murine model of visceral leishmaniasis, resulting in the observation of a dose-dependent reduction of the parasitic burden in the liver and spleen without overt toxicity effects at 2.8, 5.6, and 11.1 mg/kg per animal when administered intravenously. "
2.	Colonic Neoplasms (Colon Cancer) 03/27/2015 - "Of the compounds tested, northalrugosidine (1) showed the most potent in vitro activity against Leishmania donovani promastigotes (0.28 μM) and the highest selectivity (29.3-fold) versus its general cytotoxicity against HT-29 human colon adenocarcinoma cells. "